DOCS vs. CURY, TIFS, DAL, CVSG, WOSG, THG, AO, PPH, JDW, and CRN
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Currys (CURY), TI Fluid Systems (TIFS), Dalata Hotel Group (DAL), CVS Group (CVSG), Watches of Switzerland Group (WOSG), THG (THG), AO World (AO), PPHE Hotel Group (PPH), J D Wetherspoon (JDW), and Cairn Homes (CRN). These companies are all part of the "consumer cyclical" sector.
Dr. Martens (LON:DOCS) and Currys (LON:CURY) are both small-cap consumer cyclical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
Dr. Martens has a net margin of 10.56% compared to Currys' net margin of 0.44%. Dr. Martens' return on equity of 29.07% beat Currys' return on equity.
Dr. Martens pays an annual dividend of GBX 6 per share and has a dividend yield of 7.6%. Currys pays an annual dividend of GBX 3 per share and has a dividend yield of 4.2%. Dr. Martens pays out 6,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Currys pays out 7,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.
Dr. Martens has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Currys has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
In the previous week, Currys had 23 more articles in the media than Dr. Martens. MarketBeat recorded 26 mentions for Currys and 3 mentions for Dr. Martens. Currys' average media sentiment score of 0.34 beat Dr. Martens' score of 0.30 indicating that Currys is being referred to more favorably in the news media.
Dr. Martens has higher earnings, but lower revenue than Currys. Dr. Martens is trading at a lower price-to-earnings ratio than Currys, indicating that it is currently the more affordable of the two stocks.
Dr. Martens currently has a consensus target price of GBX 177.50, indicating a potential upside of 125.26%. Currys has a consensus target price of GBX 80.50, indicating a potential upside of 14.18%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Currys.
Currys received 700 more outperform votes than Dr. Martens when rated by MarketBeat users. However, 91.67% of users gave Dr. Martens an outperform vote while only 77.96% of users gave Currys an outperform vote.
73.3% of Dr. Martens shares are owned by institutional investors. Comparatively, 92.2% of Currys shares are owned by institutional investors. 2.8% of Dr. Martens shares are owned by company insiders. Comparatively, 18.5% of Currys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Dr. Martens beats Currys on 11 of the 20 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Martens Competitors List
Related Companies and Tools
